No Data
No Data
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?
Verve Therapeutics Slides As Insider Purchases Lose Another US$65k
Stifel Maintains Verve Therapeutics(VERV.US) With Buy Rating
Stifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)
Verve Therapeutics Has Positive Read From NewAmsterdam Data, Says Stifel